Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals

被引:195
作者
Hume, SP [1 ]
Gunn, RN [1 ]
Jones, T [1 ]
机构
[1] Hammersmith Hosp, Imperial Coll, Sch Med,MRC, Cyclotron Unit,PET Methodol Grp, London W12 0NN, England
关键词
small animal positron emission tomography; tracer kinetics; CFT; raclopride; WAY-100635;
D O I
10.1007/s002590050211
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
With the stated aim of scanning small regions of interest in mice, several high-resolution positron emission tomographic (PET) systems are presently under development. Some, however, have low sensitivity and require high doses of radioactivity to achieve count statistics adequate to reconstruct small volumes. Using in vivo dissociation constants for three carbon-11 labelled ligands previously measured in rat brain, the present paper utilises simple saturation kinetics to estimate the limits on radioactivity and specific activity, to minimise the degree of receptor occupancy and achieve maximal specific binding of the radioligand. The extent of the problem is exemplified by considering a high-affinity ligand (dissociation constant in vitro similar to 0.1 nM; in vivo similar to 5 nmol/kg i.v. injected dose), where routinely produced levels of specific activity (similar to 100 MBq/nmol) would limit the activity injected into mice to similar to 0.1 MBq for a 1% receptor occupancy. If, as is feasible, the new generation of high resolution PET systems requires an injected activity >10 MBq, then a >100-fold increase in specific activity would be needed for tracer kinetics to hold. The paper highlights the need to consider realistically achievable goals if high-resolution PET is to be accepted as a viable methodology to acquire pharmacologically and physiologically accurate ligand-receptor binding data in mice.
引用
收藏
页码:173 / 176
页数:4
相关论文
共 14 条
[1]   Three-dimensional performance of a small-diameter positron emission tomograph [J].
Bloomfield, PM ;
Myers, R ;
Hume, SP ;
Spinks, TJ ;
Lammertsma, AA ;
Jones, T .
PHYSICS IN MEDICINE AND BIOLOGY, 1997, 42 (02) :389-400
[2]  
Brownell AL, 1996, J NUCL MED, V37, P1186
[3]  
CHERRY SR, 1997, NEUROIMAGE, V5, pB9
[4]   QUANTITATIVE-ANALYSIS OF D2 DOPAMINE RECEPTOR-BINDING IN THE LIVING HUMAN-BRAIN BY PET [J].
FARDE, L ;
HALL, H ;
EHRIN, E ;
SEDVALL, G .
SCIENCE, 1986, 231 (4735) :258-261
[5]   POSITRON EMISSION TOMOGRAPHIC IMAGING OF THE DOPAMINE TRANSPORTER WITH C-11 WIN 35,428 REVEALS MARKED DECLINES IN MILD PARKINSONS-DISEASE [J].
FROST, JJ ;
ROSIER, AJ ;
REICH, SG ;
SMITH, JS ;
EHLERS, MD ;
SNYDER, SH ;
RAVERT, HT ;
DANNALS, RF .
ANNALS OF NEUROLOGY, 1993, 34 (03) :423-431
[6]   THE SELECTIVE 5-HT1A ANTAGONIST RADIOLIGAND [H-3] WAY-100635 LABELS BOTH G-PROTEIN-COUPLED AND FREE 5-HT1A RECEPTORS IN RAT-BRAIN MEMBRANES [J].
GOZLAN, H ;
THIBAULT, S ;
LAPORTE, AM ;
LIMA, L ;
HAMON, M .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 288 (02) :173-186
[7]   EVALUATION OF [O-METHYL-H-3]WAY-100635 AS AN IN-VIVO RADIOLIGAND FOR 5-HT1A RECEPTORS IN RAT-BRAIN [J].
HUME, SP ;
ASHWORTH, S ;
OPACKAJUFFRY, J ;
AHIER, RG ;
LAMMERTSMA, AA ;
PIKE, VW ;
CLIFFE, IA ;
FLETCHER, A ;
WHITE, AC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 271 (2-3) :515-523
[8]   EFFECT OF L-DOPA AND 6-HYDROXYDOPAMINE LESIONING ON [C-11] RACLOPRIDE BINDING IN RAT STRIATUM, QUANTIFIED USING PET [J].
HUME, SP ;
OPACKAJUFFRY, J ;
MYERS, R ;
AHIER, RG ;
ASHWORTH, S ;
BROOKS, DJ ;
LAMMERTSMA, AA .
SYNAPSE, 1995, 21 (01) :45-53
[9]   In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner [J].
Hume, SP ;
Brown, DJ ;
Ashworth, S ;
Hirani, E ;
Luthra, SK ;
Lammertsma, AA .
JOURNAL OF NEUROSCIENCE METHODS, 1997, 76 (01) :45-51
[10]   SPECIFIC INVITRO AND INVIVO BINDING OF H-3-RACLOPRIDE - A POTENT SUBSTITUTED BENZAMIDE DRUG WITH HIGH-AFFINITY FOR DOPAMINE D-2 RECEPTORS IN THE RAT-BRAIN [J].
KOHLER, C ;
HALL, H ;
OGREN, SO ;
GAWELL, L .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (13) :2251-2259